Let's Win Pancreatic CancerPancreatic

New Data Support Preoperative Chemoradiation Regimen for Borderline Resectable Pancreatic Cancer (Part 1/2)

In short

The Alliance A021501 trial found that neoadjuvant chemotherapy with modified FOLFIRINOX (mFOLFIRINOX) improved survival for patients with borderline resectable pancreatic cancer, making it a reference starting point before surgery. Lead investigator Dr. Matthew Katz explains what the results mean, why radiation's role remains an open question, and what research still needs to happen to help identify which patients might benefit from adding radiation.

  • •If you have borderline resectable pancreatic cancer, ask your doctor whether neoadjuvant mFOLFIRINOX — chemotherapy given before surgery — is right for your situation, since this trial showed an 18-month survival rate of 66.4% and a median overall survival of 29.8 months with this approach.
  • •Among patients who completed preoperative mFOLFIRINOX and went on to surgery, 88% achieved clean margins and 18-month survival reached 93.1% — ask your care team what your chances of reaching surgery look like after chemotherapy.
  • •Radiation before surgery is not ruled out, but this trial did not find it beneficial when added to chemotherapy for borderline resectable patients as a group — ask whether your tumor's specific features might change that calculation for you.
  • •Researchers are planning new trials to identify which patients might benefit from adding radiation to chemotherapy before surgery — ask your doctor about clinical trial eligibility, since participation could help answer this question.

Ask anything about this — free, no signup

Instant answers grounded in real guidelines, not the internet.

Surgery remains the only potential cure for pancreatic cancer. For patients with borderline resectable disease, downstaging and downsizing the tumor becomes particularly important. Neoadjuvant treatment regimens of chemotherapy or radiation are typically administered with the hope that surgery can take place and microscopic distant metastases will be eliminated.

Currently, there is no guideline as to what neoadjuvant regimen may work best for these patients. New data on the Alliance A021501 study presented at the 2021 ASCO GI Cancers Symposium potentially helped answer that question. But they also raised a few more. According to the study results , a reference regimen for these patients is neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX).

This regimen improved survival for patients with borderline resectable disease relative to historical data, explains surgical oncologist Dr. Matthew Katz . Katz is the lead investigator of the Alliance A021501 study, part of the Alliance for Clinical Trials in Oncology .

Patients in this study were randomized to receive either eight cycles of modified FOLFIRINOX or seven cycles of modified FOLFIRINOX then stereotactic body radiation therapy (SBRT) prior to anticipated pancreatectomy. 4%. 3%.

Radiotherapy May Still Have a Role Although chemotherapy with mFOLFIRINOX represents a reference preoperative regimen for patients with borderline resectable pancreatic cancer, it does not mean that radiation may not potentially have a role in the preoperative setting, says Katz, chief of the Pancreatic Surgery Service at The University of Texas MD Anderson Cancer Center , Houston. “Radiation is not dead in the water,” he explains.

“The trial was not designed to directly compare its treatment arms. But its results are being seen through the lens of preexisting bias and its results contorted to fit that bias. Some people feel very strongly that preoperative radiation is beneficial, and argue that this trial’s results are an artefact of poor trial design. ” Neither viewpoint is actually correct.

Pancreatic cancer is notoriously heterogeneous, meaning that one patient’s tumor is not like another patient’s tumor even though they may look the same. “The problem is that we are trying to demonstrate a role for radiation in a population of patients selected only on the basis of shared anatomy of the primary tumor. Radiation probably helps certain patients, but we don’t yet have a clear picture of who those patients are.

It doesn’t seem to help just one anatomic stage of patients,” Katz adds. “We need clinical markers of who will benefit from radiation, and this study just wasn’t designed to do that. ” ASCO guidelines recommend that preoperative therapy be given to patients with localized pancreatic cancer who have tumors that have a significant radiographic interface with the major mesenteric blood vessels.

It’s these patients who are at “high risk for a margin-positive operation and short survival,” when pancreatectomy is performed without prior treatment, says Katz. “But the issue is: though we often give both chemotherapy and radiation to these borderline patients, the optimal regimen in this setting is controversial,” he continues.

About the Study To better reflect differences in practice patterns, Alliance A021501 was designed with one neoadjuvant regimen that included radiation therapy and one that did not, Katz explains. Patients without disease progression following preoperative treatment underwent a pancreatectomy followed by four cycles of postoperative FOLFOX.

Of the 126 patients with borderline resectable pancreatic adenocarcinoma who participated in the study, 110 were randomly assigned to either eight cycles of mFOLFIRINOX or seven cycles of mFOLFIRINOX followed by five days of hypofractionated radiation using either SBRT or image-guided radiation treatment.

An additional 16 patients were assigned to mFOLFIRINOX alone after the radiation-treatment arm was closed at the first interim analysis due to too few patients moving on to pancreatectomy. 8 months, and a median event-free survival duration of 15 months. 1%. 2 months. 9%. The Take-Home Message Katz emphasizes there is “absolutely no question Arm B was unsuccessful and patients on chemotherapy (Arm A) did really well,” he adds.

But it’s important to think about radiation in the context of other studies. “The way I think about this study is: we wanted to find one or more preoperative backbone regimens that we could then add novel stuff to—not to compare the regimens directly,” he says. “Is chemo a good backbone? Yes. Is chemotherapy then radiation a good backbone? The answer is that we still don’t know.

When you think about a big group of patients selected only on the basis of the radiographic appearance of their tumor, it doesn’t seem like it. But I do believe there is a population of patients with localized pancreatic cancer who will benefit from radiation prior to surgery. ” Katz says it’s imperative to run more trials to help determine markers that can be used to better select patients who may benefit from both radiation and surgery.

“We need to figure out which patients benefit most from local control, and we know from studies that radiation does improve local control,” he says. Katz and colleagues are currently proposing a study through Alliance to better determine what patients may benefit from local therapy.

Highlights

from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.

Want to learn more about your specific case?

Upload your medical records and ask Navis questions tailored to your diagnosis.